CJC-1295 (No DAC) / Ipamorelin Blend (5/5mg) is a research peptide formulation combining two well-studied synthetic peptides commonly examined in growth hormone–related signaling research: CJC-1295 without DAC and Ipamorelin. CJC-1295 (No DAC) is a growth hormone–releasing hormone (GHRH) analog designed without a drug affinity complex to support short-duration signaling studies, while Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin activity without significant impact on cortisol or prolactin pathways. Together, this blend is formulated for laboratory research focused on pulsatile growth hormone release and downstream cellular signaling mechanisms.
Prior to the development of these targeted peptides, research into growth hormone stimulation and regulatory pathways relied largely on non-selective secretagogues and broader endocrine interventions. In controlled research environments, CJC-1295 (No DAC) has been studied for its ability to stimulate endogenous growth hormone release through GHRH receptor activation, while Ipamorelin has been researched for its selective binding to ghrelin receptors and its role in amplifying growth hormone pulses. The combination allows researchers to examine complementary mechanisms involved in endocrine signaling, metabolic regulation, and cellular recovery models.
Currently, the CJC-1295 (No DAC) / Ipamorelin Blend is being investigated for potential applications in growth hormone secretion studies, metabolic signaling research, cellular recovery pathways, and age-related endocrine research models. Additional studies continue to explore its role in circadian hormone rhythm research and anabolic signaling cascades. Due to the synergistic research interest of these peptides, this blend remains a valuable subject for ongoing laboratory investigation.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
The CJC-1295 (without DAC) and Ipamorelin blend is a dual-pathway research formulation designed for controlled laboratory investigation of growth hormone signaling, pulsatile secretion patterns, and downstream endocrine responses. By combining a GHRH analogue with a ghrelin-receptor agonist, this blend allows researchers to evaluate coordinated stimulation of the growth hormone axis across complementary receptor systems.
This formulation is frequently used in preclinical research models where the goal is to observe how synchronized signaling inputs influence GH release timing, amplitude, and downstream biomarkers such as IGF-1 expression, metabolic regulation, and tissue-repair signaling. Compared to single-agent studies, combination frameworks like this enable more precise mapping of upstream signaling interactions and feedback loops.
Blend Research Specifications:
| Product Format | Dual-peptide research blend |
| Composition | CJC 1295 (without DAC) 5mg + Ipamorelin 5mg |
| Unit Quantity | 1 vial |
| Purity / Identity | Research-grade material supported by lot-level analytical verification |
| Appearance | Lyophilized powder |
| Source | Chemical synthesis for laboratory research use |
| Storage Conditions | Store lyophilized blend at or below -20 °C, protected from light and moisture. Reconstituted solutions should be handled under sterile conditions and stored according to laboratory SOPs. |
| Research Use Only | This blend is supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
This blend is structured around two distinct but complementary signaling mechanisms. CJC 1295 (without DAC) acts as a GHRH analogue, stimulating the pituitary to release growth hormone through GHRH receptor activation. In contrast, Ipamorelin targets the ghrelin receptor (GHS-R1a), triggering GH release through a separate signaling pathway.
When studied together, these compounds provide a model for dual-receptor activation, allowing researchers to observe whether combined signaling produces additive or synergistic effects on GH pulse frequency, amplitude, and downstream endocrine markers. This makes the blend particularly valuable for understanding how the growth hormone axis behaves under coordinated stimulation rather than isolated input.
Unlike long-acting GHRH analogues, the “no DAC” version of CJC-1295 is often used in research contexts focused on pulsatile GH release patterns rather than sustained elevation. This distinction allows for more precise timing-based study designs, particularly when comparing natural secretion rhythms to induced responses.
Important Research Notice: Nordsci peptides are supported by independent analytical testing to validate identity and purity. A Certificate of Analysis is available for each lot to support laboratory documentation, reproducibility, and quality-control standards.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
The primary application of this blend is in GH pulse modeling. Researchers can track how dual-pathway stimulation affects pulse timing, magnitude, and recovery intervals. These models are essential for understanding how GH secretion behaves under different signaling conditions and how closely induced pulses align with endogenous patterns.
Because GH signaling influences IGF-1 production and other endocrine markers, this blend is often used in studies that monitor downstream effects of GH release. Investigators may track changes in IGF-1 levels, metabolic signaling markers, and tissue-repair indicators to determine how upstream stimulation translates into measurable biological outcomes.
The blend is frequently compared against single-agent protocols involving either GHRH analogues or ghrelin mimetics alone. These comparisons help researchers determine whether dual-pathway activation produces clearer or more consistent data, particularly in studies where signal variability is a concern.
Growth hormone signaling is closely tied to tissue repair, recovery dynamics, and metabolic regulation. In recovery-focused research, this blend may be evaluated alongside structural repair compounds such as BPC 157 or remodeling-focused peptides like Thymosin Beta 4 to assess how endocrine signaling influences overall recovery outcomes.
Because this is a multi-compound formulation, consistency in preparation and handling is critical. Laboratories typically standardize reconstitution methods, storage conditions, and dosing intervals to reduce variability across study groups. Timing is especially important in GH-axis research, where small differences in administration schedules can significantly affect observed outcomes.
Maintaining detailed records of lot numbers, preparation methods, and storage conditions helps ensure reproducibility and supports internal quality-control processes. Researchers should align all handling procedures with institutional SOPs and regulatory requirements governing peptide research.
For GH-axis research, sourcing quality directly impacts data integrity. Reliable suppliers provide consistent synthesis standards, transparent documentation, and clear handling guidance. Nordsci Peptides supports laboratory research with products designed for controlled experimental use and supported by analytical verification.
Procurement Best Practices
IMPORTANT: This blend is intended strictly for laboratory research. It is not for human consumption, clinical application, or veterinary use.
